Harbin Medisan Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.59%

Harbin Medisan Pharmaceutical Co Ltd (002900) has an Asset Resilience Ratio of 2.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Harbin Medisan Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥93.31 Million
≈ $13.65 Million USD Cash + Short-term Investments

Total Assets

CN¥3.61 Billion
≈ $528.15 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002900 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Harbin Medisan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Harbin Medisan Pharmaceutical Co Ltd (002900) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥93.31 Million 2.59%
Total Liquid Assets CN¥93.31 Million 2.59%

Asset Resilience Insights

  • Limited Liquidity: Harbin Medisan Pharmaceutical Co Ltd maintains only 2.59% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Harbin Medisan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Harbin Medisan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Harbin Medisan Pharmaceutical Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Harbin Medisan Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.27% CN¥48.08 Million
≈ $7.04 Million
CN¥3.80 Billion
≈ $556.13 Million
-0.41pp
2023-12-31 1.68% CN¥57.75 Million
≈ $8.45 Million
CN¥3.44 Billion
≈ $503.82 Million
-1.11pp
2022-12-31 2.78% CN¥91.25 Million
≈ $13.35 Million
CN¥3.28 Billion
≈ $479.50 Million
-16.19pp
2021-12-31 18.97% CN¥581.68 Million
≈ $85.12 Million
CN¥3.07 Billion
≈ $448.58 Million
+4.44pp
2020-12-31 14.53% CN¥360.79 Million
≈ $52.80 Million
CN¥2.48 Billion
≈ $363.31 Million
-11.54pp
2019-12-31 26.07% CN¥696.72 Million
≈ $101.95 Million
CN¥2.67 Billion
≈ $391.02 Million
+21.90pp
2018-12-31 4.17% CN¥104.91 Million
≈ $15.35 Million
CN¥2.51 Billion
≈ $367.81 Million
--
pp = percentage points

About Harbin Medisan Pharmaceutical Co Ltd

SHE:002900 China Drug Manufacturers - Specialty & Generic
Market Cap
$535.14 Million
CN¥3.66 Billion CNY
Market Cap Rank
#12192 Global
#3761 in China
Share Price
CN¥11.56
Change (1 day)
+0.09%
52-Week Range
CN¥10.66 - CN¥16.70
All Time High
CN¥32.63
About

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more